- Home
- PXLW vs NXTC Comparison
PXLW vs NXTC Comparison
Compare PXLW & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PXLW
- NXTC
- Stock Information
- Founded
- PXLW 1997
- NXTC 2015
- Country
- PXLW United States
- NXTC United States
- Employees
- PXLW N/A
- NXTC N/A
- Industry
- PXLW Semiconductors
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- PXLW Technology
- NXTC Health Care
- Exchange
- PXLW Nasdaq
- NXTC Nasdaq
- Market Cap
- PXLW 41.8M
- NXTC 40.3M
- IPO Year
- PXLW 2000
- NXTC 2019
- Fundamental
- Price
- PXLW $0.81
- NXTC $1.37
- Analyst Decision
- PXLW Strong Buy
- NXTC Strong Buy
- Analyst Count
- PXLW 3
- NXTC 2
- Target Price
- PXLW $2.17
- NXTC $4.00
- AVG Volume (30 Days)
- PXLW 243.1K
- NXTC 43.8K
- Earning Date
- PXLW 11-12-2024
- NXTC 11-07-2024
- Dividend Yield
- PXLW N/A
- NXTC N/A
- EPS Growth
- PXLW N/A
- NXTC N/A
- EPS
- PXLW N/A
- NXTC N/A
- Revenue
- PXLW $54,190,000.00
- NXTC N/A
- Revenue This Year
- PXLW N/A
- NXTC N/A
- Revenue Next Year
- PXLW $32.81
- NXTC N/A
- P/E Ratio
- PXLW N/A
- NXTC N/A
- Revenue Growth
- PXLW N/A
- NXTC N/A
- 52 Week Low
- PXLW $0.61
- NXTC $1.03
- 52 Week High
- PXLW $3.08
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- PXLW 59.04
- NXTC 53.73
- Support Level
- PXLW $0.66
- NXTC $1.30
- Resistance Level
- PXLW $0.71
- NXTC $1.60
- Average True Range (ATR)
- PXLW 0.05
- NXTC 0.08
- MACD
- PXLW 0.01
- NXTC 0.01
- Stochastic Oscillator
- PXLW 83.29
- NXTC 45.91
About PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in China.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.